Lantheus Holdings Inc stock (US5156731020): analysts see upside after recent volatility

Lantheus Holdings Inc shares have been volatile, while Wall Street analysts still see upside over the next 12 months. What is driving sentiment around the US diagnostics and theranostics specialist?

Lantheus Holdings Inc has remained in focus among healthcare investors as Wall Street analysts continue to project upside for the stock over the next 12 months, despite recent share price volatility on Nasdaq. According to MarketBeat, the consensus 12?month price target from 11 analysts stands around 99.71 USD with a range between 80 and 115 USD, based on data referenced on 05/15/2026, implying mid?single?digit percentage upside versus recent levels MarketBeat as of 05/15/2026. On 05/15/2026, the stock closed at roughly 93.91 USD on Nasdaq, according to price information cited by Investing.com on 05/16/2026 Investing.com as of 05/16/2026.

As of: 17.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Lantheus Holdings Inc
• Sector/industry: Medical diagnostics, radiopharmaceuticals, theranostics
• Headquarters/country: Bedford, Massachusetts, United States
• Core markets: Diagnostic imaging and radiopharmaceutical agents for cardiology and oncology, primarily North America with growing international exposure
• Key revenue drivers: Radiopharmaceutical agents such as PYLARIFY for prostate cancer imaging and other diagnostic imaging products
• Home exchange/listing venue: Nasdaq (ticker: LNTH)
• Trading currency: USD

Lantheus Holdings Inc: core business model

Lantheus Holdings Inc is a specialty healthcare company focused on diagnostic imaging agents and theranostic solutions that support disease detection and treatment decisions, particularly in cardiology and oncology. The group traces its roots back to 1956 and operates from Bedford, Massachusetts, providing products that are used in nuclear medicine and other imaging modalities to help clinicians visualize organ function and disease processes Investing.com company profile as of 05/16/2026. Its portfolio includes radiopharmaceuticals that are injected into patients and then imaged with modalities such as PET or SPECT scanners.

The company’s business model centers on developing, manufacturing and commercializing specialized contrast agents and tracers that can command premium pricing due to their highly regulated nature, clinical differentiation and limited competition. Lantheus typically works closely with hospitals, imaging centers and radiopharmacies, supplying products that are ordered for specific procedures and often reimbursed under established coding systems in the US and other markets. This creates recurring revenue streams tied to procedure volumes rather than long?term equipment sales, and exposes the company to trends in imaging utilization and healthcare policy.

In addition to organic development of new imaging agents, Lantheus has pursued partnerships and acquisitions to expand its pipeline and address new disease areas. The company has emphasized theranostics, an approach that combines targeted diagnostics with therapeutic applications built on similar molecular targets. According to information highlighted on the Korean edition of Investing.com, Lantheus collaborates with partners such as Regeneron Pharmaceuticals and others in the imaging and theranostics ecosystem, indicating a strategy of leveraging external innovation alongside internal R&D Investing.com Korea as of 05/16/2026.

Main revenue and product drivers for Lantheus Holdings Inc

A key contributor to Lantheus’s recent performance has been PYLARIFY, a PET imaging agent used in prostate?specific membrane antigen (PSMA)?targeted imaging for prostate cancer patients. The product allows clinicians to visualize cancer lesions more accurately, supporting staging and treatment planning, and has been described in market commentary as Lantheus’s flagship product in the theranostics segment Investing.com Korea as of 05/16/2026. PYLARIFY revenue is closely linked to the adoption of PSMA?PET guidelines and broader uptake of advanced imaging in prostate cancer management, particularly in the United States where reimbursement frameworks have been established.

Beyond PYLARIFY, Lantheus markets a range of established imaging agents and contrast media that have been used in cardiology for decades, supporting stress testing and evaluation of myocardial perfusion. These legacy products typically face slower growth but can generate stable cash flows that help fund newer initiatives. The company also focuses on expanding into neurodegenerative disease imaging, including Alzheimer’s diagnostics, an area highlighted as a strategic focus following its acquisition of Life Molecular Imaging. Commentators note that this acquisition, valued at around 350 million USD, is expected to accelerate Lantheus’s Alzheimer’s segment and contribute to earnings from the first year after closing, according to summaries on Investing.com’s Korean platform published in 2024 and referenced again in 2026 market overviews Investing.com Korea as of 05/16/2026.

Financial metrics often used to assess Lantheus’s valuation include the price?to?earnings ratio and price?to?sales ratio versus medical device and life science peers. Simply Wall St, comparing another medical stock with peers in an article updated in early 2026, referenced a P/E ratio of roughly 21.9x for Lantheus, positioning it above some diversified healthcare names but below high?growth device makers Simply Wall St as of 02/14/2026. On Investing.com’s Spanish?language pages, valuation tables for Lantheus as of 05/16/2026 show a trailing price?to?earnings multiple in the low?20s and a price?to?sales ratio around 3.6x, underlining that investors are paying a premium for the company’s growth profile while still within the broader range for specialized healthcare firms Investing.com valuation table as of 05/16/2026.

Analyst expectations, as aggregated by MarketBeat on 05/15/2026, suggest that Lantheus could deliver further earnings and revenue growth over the coming year, supporting the mid?single?digit implied upside in the consensus target versus the recent share price. The same data set indicates that the majority of covering analysts rate the stock in the “moderate buy” category, reflecting a generally positive but not euphoric stance on risk?reward MarketBeat as of 05/15/2026. For investors, these forecasts are typically built on projected procedure growth for key imaging agents, the ramp?up of Alzheimer’s?related products from the Life Molecular Imaging acquisition, and the company’s ability to navigate pricing and reimbursement challenges.

Industry trends and competitive position

Lantheus operates in the intersection of medical imaging, radiopharmaceuticals and emerging theranostic therapies, a space that has attracted increasing attention as precision medicine gains traction. The company competes with large diversified players such as GE HealthCare in diagnostic imaging, as well as specialist radiopharmaceutical companies and newer biotech entrants targeting targeted radionuclide therapies. According to commentary on the Korean Investing.com platform, Lantheus is viewed as a leader in theranostics with a strong product portfolio anchored by PYLARIFY and a strategic push into Alzheimer’s diagnostics, which could broaden its addressable market beyond oncology and cardiology Investing.com Korea as of 05/16/2026.

At the same time, the medical diagnostics sector is characterized by pricing pressure and ongoing regulatory scrutiny. Analysts following Lantheus have pointed to intensifying competition and payer efforts to manage imaging utilization as key challenges. An overview on Investing.com’s Korean site mentions that analysts have discussed target price ranges between roughly 112 and 143 USD for Lantheus at earlier stages, while also highlighting market headwinds such as price competition in diagnostic imaging and evolving reimbursement criteria Investing.com Korea as of 05/16/2026. These dynamics mean that execution on product launches, clinical differentiation and payer engagement are critical for maintaining margins and growth.

Another factor for Lantheus is investor sentiment toward healthcare innovation and small? to mid?cap growth stocks more broadly. As interest rates and sector rotations influence capital flows, companies reliant on future growth can experience amplified share price swings. Secondary data sources indicate that Lantheus has at times appeared in lists of heavily shorted healthcare names, with MarketBeat reporting a short interest ratio above 8% for the company in a broader overview of biotech and healthcare short positions in early 2026, suggesting that some investors are positioning for downside volatility MarketBeat short?interest overview as of 03/31/2026. Elevated short interest can both pressure the stock and set the stage for sharp moves if sentiment shifts.

Why Lantheus Holdings Inc matters for US investors

For US investors, Lantheus represents exposure to a specialized corner of the healthcare market that sits between traditional pharmaceuticals and medical devices. Its Nasdaq listing under ticker LNTH makes it accessible through most US brokerage platforms, and its business is closely tied to trends in US healthcare spending, Medicare and commercial payer reimbursement, and the adoption of advanced imaging in community and academic centers. As US healthcare systems continue to emphasize early detection and personalized treatment, demand for precise diagnostic information tends to support utilization of nuclear imaging procedures in conditions such as prostate cancer and, potentially, Alzheimer’s disease.

US?based shareholders also track Lantheus as part of a broader investment theme around theranostics, where diagnostic and therapeutic capabilities are linked via the same biological targets. While Lantheus itself is primarily known for diagnostics, its positioning in PSMA?targeted imaging and Alzheimer’s PET agents connects it to larger therapeutic pipelines being developed by pharmaceutical partners. This could influence collaboration opportunities, licensing deals and long?term revenue streams tied to companion diagnostics. As a result, Lantheus may appear in thematic portfolios focused on oncology innovation, neurodegeneration, or precision medicine within the US equity universe.

Conclusion

Lantheus Holdings Inc sits at the center of several powerful trends in healthcare, including the growth of precision diagnostics, the adoption of PSMA?PET imaging in prostate cancer and the push to better detect neurodegenerative diseases. Recent data from MarketBeat show that the stock traded around the mid?90 USD range on 05/15/2026 with consensus analyst price targets implying mid?single?digit upside over the next 12 months and a “moderate buy” stance overall MarketBeat as of 05/15/2026. At the same time, sector?wide pricing pressure, intensifying competition and noticeable short interest underscore that the investment case involves meaningful risks alongside the potential rewards. Investors who follow the name typically monitor product uptake trends, regulatory and reimbursement developments, and the company’s execution on acquisitions such as Life Molecular Imaging when assessing future prospects.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.